Health Equity in Obesity Care

The promise of GLP-1 therapeutics has thrown disparities into sharp relief: list prices exceed $1,000 per month, Medicare Part D coverage remains restricted to cardiovascular and MASH indications, and Black, Hispanic, and rural patients are underrepresented in both clinical trials and prescribing. The track will examine weight stigma in clinical encounters (the Rudd Center evidence base), patient-first language, structural racism and the social determinants of obesity, and policy levers including the Treat and Reduce Obesity Act. Sessions will also address culturally tailored interventions and community-based participatory research.